Patents by Inventor Deba P. Saha
Deba P. Saha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9528125Abstract: The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB.Type: GrantFiled: January 28, 2015Date of Patent: December 27, 2016Assignee: Merck Sharp & Dohme Corp.Inventor: Deba P. Saha
-
Publication number: 20150197772Abstract: The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB.Type: ApplicationFiled: January 28, 2015Publication date: July 16, 2015Applicant: MERCK SHARP & DOHME CORP.Inventor: Deba P. Saha
-
Patent number: 9080177Abstract: This application provides, in part, pAVEC plasmids and methods of use of such plasmids for the production of polypeptides such as immunoglobulins as well as the generation of recombined versions of such plasmids which contain polynucleotides encoding such polypeptides.Type: GrantFiled: April 2, 2012Date of Patent: July 14, 2015Assignee: MERCK SHARP & DOHME CORP.Inventor: Deba P. Saha
-
Patent number: 8951790Abstract: The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB.Type: GrantFiled: January 6, 2012Date of Patent: February 10, 2015Assignee: Merck Sharp & Dohme Corp.Inventor: Deba P. Saha
-
Patent number: 8673630Abstract: The present invention provides polynucleotides for enhanced expression of a target gene such as an immunoglobulin. Methods of expressing a target gene using the polynucleotides of the invention are also covered.Type: GrantFiled: November 12, 2009Date of Patent: March 18, 2014Assignee: Merck, Sharp & Dohme Corp.Inventor: Deba P. Saha
-
Publication number: 20140030760Abstract: This application provides, in part, pAVEC plasmids and methods of use of such plasmids for the production of polypeptides such as immunoglobulins as well as the generation of recombined versions of such plasmids which contain polynucleotides encoding such polypeptides.Type: ApplicationFiled: April 2, 2012Publication date: January 30, 2014Applicant: MERCK SHARP & DOHME CORP.Inventor: Deba P. Saha
-
Patent number: 8470593Abstract: The present invention provides a plasmid system which facilitates the construction of a single amplifiable plasmid that, having the potential to accommodate many independent expression cassettes, has the ability to express multi-subunit complex proteins such as antibodies and receptors.Type: GrantFiled: October 18, 2011Date of Patent: June 25, 2013Assignee: Merck Sharp Dohme & Corp.Inventor: Deba P. Saha
-
Publication number: 20120142056Abstract: The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB.Type: ApplicationFiled: January 6, 2012Publication date: June 7, 2012Inventor: Deba P. Saha
-
Patent number: 8137933Abstract: The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB.Type: GrantFiled: November 12, 2009Date of Patent: March 20, 2012Assignee: Schering CorporationInventor: Deba P. Saha
-
Publication number: 20120040402Abstract: The present invention provides a plasmid system which facilitates the construction of a single amplifiable plasmid that, having the potential to accommodate many independent expression cassettes, has the ability to express multi-subunit complex proteins such as antibodies and receptors.Type: ApplicationFiled: October 18, 2011Publication date: February 16, 2012Applicant: Schering CorporationInventor: Deba P. Saha
-
Patent number: 8062886Abstract: The present invention provides a plasmid system which facilitates the construction of a single amplifiable plasmid that, having the potential to accommodate many independent expression cassettes, has the ability to express multi-subunit complex proteins such as antibodies and receptors.Type: GrantFiled: November 19, 2007Date of Patent: November 22, 2011Assignee: Schering CorporationInventor: Deba P. Saha
-
Publication number: 20110217695Abstract: The present invention provides polynucleotides for enhanced expression of a target gene such as an immunoglobulin. Methods of expressing a target gene using the polynucleotides of the invention are also covered.Type: ApplicationFiled: November 12, 2009Publication date: September 8, 2011Applicant: Schering CorporationInventor: Deba P. Saha
-
Publication number: 20100120090Abstract: The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB.Type: ApplicationFiled: November 12, 2009Publication date: May 13, 2010Inventor: Deba P. Saha
-
Publication number: 20080311623Abstract: The present invention provides a plasmid system which facilitates the construction of a single amplifiable plasmid that, having the potential to accommodate many independent expression cassettes, has the ability to express multi-subunit complex proteins such as antibodies and receptors.Type: ApplicationFiled: November 19, 2007Publication date: December 18, 2008Inventor: Deba P. Saha
-
Publication number: 20080166373Abstract: The present invention is directed to compositions and methods for the delivery of interferon polypeptides. The invention provides recombinant viral and non-viral vectors for the selective expression of interferon polypeptides in particular cell or tissue types. The invention further provides pharmaceutically acceptable formulations of such vectors for administration to mammalian subjects. The invention further provides methods of treatment of diseases in mammalian organisms through the delivery of recombinant vectors selectively expressing interferon polypeptides.Type: ApplicationFiled: March 21, 2008Publication date: July 10, 2008Applicant: Canji, Inc.Inventors: Tattanahalli L. Nagabhushan, Deba P. Saha
-
Patent number: 7326567Abstract: The present invention provides a plasmid system which facilitates the construction of a single amplifiable plasmid that, having the potential to accommodate many independent expression cassettes, has the ability to express multi-subunit complex proteins such as antibodies and receptors.Type: GrantFiled: November 10, 2004Date of Patent: February 5, 2008Assignee: Schering CorporationInventor: Deba P. Saha
-
Publication number: 20020155095Abstract: The present invention is directed to compositions and methods for the delivery of interferon polypeptides. The invention provides recombinant viral and non-viral vectors for the selective expression of interferon polypeptides in particular cell or tissue types. The invention further provides pharmaceutically acceptable formulations of such vectors for administration to mammalian subjects. The invention further provides methods of treatment of diseases in mammalian organisms through the delivery of recombinant vectors selectively expressing interferon polypeptides.Type: ApplicationFiled: July 15, 1999Publication date: October 24, 2002Inventors: TATTANAHALLI L. NAGABHUSHAN, DEBA P. SAHA